{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Johnson SP"],"funding":["Cancer Research UK","European Research Council","Medical Research Council","National Institute for Health Research (NIHR)","Engineering and Physical Sciences Research Council"],"pagination":["7436-7447"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7611302"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(24)"],"pubmed_abstract":["<h4>Purpose</h4>Photoacoustic imaging (PAI) is a novel noninvasive and nonionizing imaging technique that allows longitudinal imaging of tumor vasculature <i>in vivo</i> and monitoring of response to therapy, especially for vascular targeted chemotherapy agents. In this study, we used a novel high-resolution all-optical PAI scanner to observe the pharmacodynamic response to the vascular-disrupting agent OXi4503.<h4>Experimental design</h4>Two models of colorectal carcinoma (SW1222 and LS174T) that possess differing pathophysiologic vascularization were established as subcutaneous tumors in mice. Monitoring of response was performed over a 16-day \"regrowth\" period following treatment at 40 mg/kg, and at day 2 for a \"dose response\" study at 40 mg/kg, 10 mg/kg, 1 mg/kg, and sham dose.<h4>Resu"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors."],"pmcid":["PMC7611302"],"funding_grant_id":["G1001497","A10331","16463","21030","741149","C1519/A10331"],"pubmed_authors":["Beard P","Pedley RB","Lythgoe MF","Johnson SP","Ogunlade O"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors.","description":"<h4>Purpose</h4>Photoacoustic imaging (PAI) is a novel noninvasive and nonionizing imaging technique that allows longitudinal imaging of tumor vasculature <i>in vivo</i> and monitoring of response to therapy, especially for vascular targeted chemotherapy agents. In this study, we used a novel high-resolution all-optical PAI scanner to observe the pharmacodynamic response to the vascular-disrupting agent OXi4503.<h4>Experimental design</h4>Two models of colorectal carcinoma (SW1222 and LS174T) that possess differing pathophysiologic vascularization were established as subcutaneous tumors in mice. Monitoring of response was performed over a 16-day \"regrowth\" period following treatment at 40 mg/kg, and at day 2 for a \"dose response\" study at 40 mg/kg, 10 mg/kg, 1 mg/kg, and sham dose.<h4>Resu","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Dec","modification":"2026-04-30T03:10:33.615Z","creation":"2022-02-10T21:40:15.754Z"},"accession":"S-EPMC7611302","cross_references":{"pubmed":["31551349"],"doi":["10.1158/1078-0432.CCR-19-0360","10.1158/1078-0432.ccr-19-0360"]}}